Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Renal Cell Carinoma : Update Bulletin [April 2015]

Product Code:
596200385
Release Date:
April 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Renal Cell Carcnoma.  Topics covered: impact of the results of the ASURE trial, ATLAS  trial and PROTECT trial, combination of Roche’s PD-L1 inhibitor MPDL3280A and Avastin, combination of MPDL3280A with varlilumab, combining the novel nanoparticle conjugate CRLX101 with Avastin as a potential treatment for relapsed RCC.

Key Questions Answered in this Update Bulletin:

  • What impact will the results of the ASURE trial have on the prospects for VEGF TKIs within the adjunctive therapy setting for metastatic RCC (mRCC)?
  • Do KOLs expect the ATLAS or PROTECT trials to provide any further data in support of the adjunctive use of VEGF TKIs?
  • What advantages could the combination of the Roche’s PD-L1 inhibitor, MPDL3280A, and Avastin offer over Avastin monotherapy in the treatment of mRCC?
  • Do KOLs believe that the combination of MPDL3280A with varlilumab, an anti-CD27 antibody, has potential as a treatment strategy for RCC?
  • Will early trial data support the rationale for combining the novel nanoparticle conjugate CRLX101 with Avastin as a potential treatment for relapsed RCC?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved